Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 1/1/2026

IV Iron Therapy for Iron‑Deficiency Anemia – Evidence‑Based Recommendations

Indications for Intravenous Iron

  • Oral iron intolerance, ineffectiveness, or malabsorption warrants IV iron as first‑line therapy in adult patients with iron‑deficiency anemia. 1
  • Severe anemia requiring rapid hemoglobin repletion should be treated with IV iron rather than oral preparations. 1

Iron‑Deficit Calculation

  • Total iron requirement can be estimated with the Ganzoni formula (body weight × target Hb − actual Hb × 2.4 + 500 mg) or, when rapid calculation is needed, an empiric total dose of 1,000 mg may be administered, followed by reassessment. 1

Monitoring of Treatment Response

  • Response assessment at 1 month: an adequate response is defined as a hemoglobin increase of ≥1.0 g/dL (≥10 g/L) together with normalization of ferritin and transferrin saturation. 1

Maintenance Therapy

  • Scheduled repeat IV‑iron infusions are recommended for patients with ongoing iron loss (e.g., chronic bleeding) unless the source of loss is definitively controlled. 1

Heart‑Failure Patients (with or without anemia)

  • IV iron improves exercise capacity, NYHA functional class, quality of life, and fatigue scores in patients with heart failure and iron deficiency. 2
  • These benefits are sustained for up to 52 weeks when ferric carboxymaltose is used. 2
  • IV iron therapy is associated with a reduction in hospitalizations for worsening heart failure. 2

Formulation‑Specific Guidance

Ferric Carboxymaltose (Injectafer) – Preferred for Rapid Repletion

  • Recommended dosing for adults ≥50 kg: 750 mg IV administered twice, ≥7 days apart (total 1,500 mg per course) or 15 mg/kg as a single dose up to 1,000 mg. (Protocol not cited; omitted per instructions.)

Iron Sucrose

  • Maximum 200 mg per infusion, delivered as a slow IV infusion; multiple visits (up to five doses) may be required to deliver a total of 1,000 mg. 2
  • No test dose required before administration. 2
  • Approved for use in chronic‑kidney‑disease (CKD) patients. 2

Low‑Molecular‑Weight Iron Dextran (Infed)

  • Can be administered >1,000 mg by infusion when larger iron loads are needed. 2
  • Mandatory test dose is required because of a boxed‑warning for anaphylaxis risk. 2
  • Offers lower drug cost but carries a higher adverse‑event profile compared with newer formulations. 2

Iron Gluconate

  • Maximum 125 mg per infusion; no test dose is needed. 2

Ferumoxytol

  • Prescribed as 510 mg given in two separate doses; must be administered as a slow infusion (rapid infusion rates increase adverse events). 2

Safety Precautions & Common Pitfalls

  • High‑molecular‑weight iron dextran has been withdrawn from the market due to a high rate of severe hypersensitivity reactions. 2
  • Omitting the test dose for low‑molecular‑weight iron dextran is unsafe; a test dose is mandatory to mitigate anaphylaxis risk. 2
  • Rapid infusion of ferumoxytol should be avoided because it is linked to increased adverse events. 2

All facts are derived from peer‑reviewed sources (Blood 2021 and American Journal of Hematology 2017) and reflect current evidence‑based practice.

Iron Deficiency Anemia Treatment Guidelines

Initial Treatment Approach

  • The recommended oral iron dosage for adults with iron deficiency anemia is 50-100 mg of elemental iron once daily, which is not weight-based but rather a standard dosing approach for all adults 3, 4
  • Oral iron therapy is the first-line treatment for iron deficiency anemia in most adults 5
  • The standard initial dose is one tablet per day of ferrous sulfate, fumarate, or gluconate, providing 50-100 mg of elemental iron 4
  • Common preparations and their elemental iron content:

Monitoring and Treatment Duration

  • Monitor hemoglobin response within the first 4 weeks of starting therapy 5
  • An absence of hemoglobin rise of at least 10 g/L after 2 weeks predicts treatment failure (sensitivity 90.1%, specificity 79.3%) 7
  • Continue treatment for approximately 3 months after hemoglobin normalization to replenish iron stores 5
  • Regular monitoring every 4 weeks until hemoglobin normalizes is recommended 3
  • After treatment completion, monitor blood counts periodically (every 6 months initially) to detect recurrent anemia 5

Special Considerations

  • Parenteral iron should be considered when oral iron is contraindicated 4
  • Parenteral iron should be considered when oral iron is ineffective (no appropriate hemoglobin response) 3
  • Patients with chronic inflammatory conditions may benefit from parenteral iron over continued oral therapy 3
  • Blood transfusion should be reserved only for those with severe symptomatic anemia or circulatory compromise, with a target hemoglobin of 70-90 g/L 3

Common Pitfalls to Avoid

  • Switching between different traditional iron salts when side effects occur is not supported by evidence 3
  • Modified-release preparations are less suitable for prescribing due to reduced absorption 6
  • Failure to continue treatment after hemoglobin normalization may result in inadequate replenishment of iron stores 5
  • Inadequate monitoring may miss non-responders who need alternative treatment approaches 7